Literature DB >> 10751137

Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.

P A Haslett1, D F Nixon, Z Shen, M Larsson, W I Cox, R Manandhar, S M Donahoe, G Kaplan.   

Abstract

Virus-specific CD4+ T-helper cell function is important in controlling human immunodeficiency virus (HIV) infection but is impaired in patients with progressive HIV disease. It has been reported that after highly active antiretroviral therapy (HAART), HIV-specific lymphoproliferative responses remain absent, whereas responses to non-HIV microbial antigens are restored. However, in analyzing immune responses in a cohort of chronically infected adults on HAART, we observed strong HIV-specific CD4+ T cell responses of Th-1 phenotype in 11 of 22 patients. The magnitude and frequency of HIV-specific lymphoproliferative responses was strongly associated with previous interruptions in HAART (P=.001). In contrast, the magnitude of CD8+ T cell responses to HIV Gag, Pol, Env, and Nef was similar in patients who had and those who had not interrupted HAART. We conclude that (1) a significant proportion of chronically HIV-infected patients on HAART can generate strong HIV-specific CD4+ and CD8+ T cell immunity and (2) transient interruptions in antiviral treatment may prime or boost HIV-specific CD4+ T-helper responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751137     DOI: 10.1086/315381

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

2.  Immune Reconstitution Strategies in HIV.

Authors:  Matthew R. Leibowitz; Ronald T. Mitsuyasu
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

Review 3.  Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.

Authors:  Ume L Abbas; John W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

4.  High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.

Authors:  A C McNeil; W L Shupert; C A Iyasere; C W Hallahan; J A Mican; R T Davey; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

5.  Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.

Authors:  Gabriel M Ortiz; Jennifer Hu; Joshua A Goldwitz; Rohit Chandwani; Marie Larsson; Nina Bhardwaj; Sebastian Bonhoeffer; Bharat Ramratnam; Linqi Zhang; Martin M Markowitz; Douglas F Nixon
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Flow cytometry evaluation of the T-cell receptor Vbeta repertoire among HIV-1 infected individuals before and after antiretroviral therapy.

Authors:  Carmem Beatriz Wagner Giacoia-Gripp; Ivan Neves; Maria Clara Galhardo; Mariza Gonçalves Morgado
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

7.  Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.

Authors:  G Carcelain; R Tubiana; A Samri; V Calvez; C Delaugerre; H Agut; C Katlama; B Autran
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.

Authors:  Annette Oxenius; Angela R McLean; Marek Fischer; David A Price; Sarah J Dawson; Roland Hafner; Christine Schneider; Helen Joller; Bernard Hirschel; Rodney E Phillips; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Immunity to human immunodeficiency virus (HIV) in children with chronic HIV infection receiving highly active antiretroviral therapy.

Authors:  Adriana Weinberg; Gregory B Pott
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

10.  Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection.

Authors:  Uma Malhotra; Sarah Holte; Tuofu Zhu; Elizabeth Delpit; Claire Huntsberry; Alessandro Sette; Raj Shankarappa; Janine Maenza; Lawrence Corey; M Juliana McElrath
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.